Ixekizumab (Genetical Recombination) Subcutaneous Injection 80mg (Taltz® / トルツ皮下注80mgオートインジェクター)

JPY ¥193,700

Japanese Humanized Anti-Human IL-17A Monoclonal Antibody (Ixekizumab (Genetical Recombination) 80mg). Subcutaneous injection for plaque psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. 1mL [1 autoinjector]. Mfd. by Eli Lilly Japan K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥178,204
10 - 19 12% JPY ¥170,456
20 + 18% JPY ¥158,834
SKU: TAL-80-INJ Category:

Description

Product Overview / 商品概要

Taltz Subcutaneous Injection 80mg Autoinjector (トルツ皮下注80mgオートインジェクター)
Generic: Ixekizumab (Genetical Recombination) / イキセキズマブ(遺伝子組換え)
Therapeutic Category: Humanized Anti-Human IL-17A Monoclonal Antibody / ヒト化抗ヒトIL-17Aモノクローナル抗体製剤
Manufactured by: Eli Lilly Japan K.K. / 日本イーライリリー株式会社

Composition & Specification / 組成・規格

Active Ingredient: Ixekizumab (Genetical Recombination) 80mg per 1 syringe / 1シリンジ中 イキセキズマブ(遺伝子組換え) 80mg
Additives: Purified sucrose 80mg, Polysorbate 80 0.3mg, Sodium hydroxide q.s. / 精製白糖 80mg、ポリソルベート80 0.3mg、水酸化ナトリウム 適量
Appearance: Colorless to slightly yellow clear solution (injection); pH 5.2–6.2; osmotic pressure ratio (relative to physiological saline) approx. 1
外観: 無色~微黄色の澄明な液(注射剤)、pH 5.2~6.2、浸透圧比(生理食塩液に対する比)約1

Indications / 効能効果

EN: The following diseases with inadequate response to existing treatments:
– Plaque psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis
– Ankylosing spondylitis, non-radiographic axial spondyloarthritis
JA: 既存治療で効果不十分な下記疾患
〇尋常性乾癬、乾癬性関節炎、膿疱性乾癬、乾癬性紅皮症
〇強直性脊椎炎、X線基準を満たさない体軸性脊椎関節炎

Dosage and Administration / 用法用量

EN:
Usually, in adults, an initial dose of 160mg is administered subcutaneously, followed by 80mg subcutaneously every 2 weeks from Week 2 to Week 12, then 80mg subcutaneously every 4 weeks thereafter. If response is inadequate at Week 12, 80mg every 2 weeks may be administered.

Usually, in adults, 80mg is administered subcutaneously every 4 weeks.
JA: 〈尋常性乾癬、乾癬性関節炎、膿疱性乾癬、乾癬性紅皮症〉
通常、成人にはイキセキズマブ(遺伝子組換え)として初回に160mgを皮下投与し、2週後から12週後までは1回80mgを2週間隔で皮下投与し、以降は1回80mgを4週間隔で皮下投与する。なお、12週時点で効果不十分な場合には、1回80mgを2週間隔で皮下投与できる。
〈強直性脊椎炎、X線基準を満たさない体軸性脊椎関節炎〉
通常、成人にはイキセキズマブ(遺伝子組換え)として1回80mgを4週間隔で皮下投与する。

Contraindications / 禁忌

EN: 2.1 Patients with serious infections
2.2 Patients with active tuberculosis
2.3 Patients with a history of hypersensitivity to any component of this product
JA: 2.1 重篤な感染症の患者
2.2 活動性結核の患者
2.3 本剤の成分に対し過敏症の既往歴を有する患者

Regulatory Information / 規制情報

Approval No.: 22800AMX00440
Sales Started: November 2016 / 2016年11月
Classification Code: 873999
Storage: Store at 2–8°C / 2~8℃で保存
Shelf Life: 24 months / 24ヵ月

Packaging / 包装

Main Package (for sale): 1mL [1 autoinjector] / 1mL[1オートインジェクター]
Other Available Packages (by special order): 1mL [1 autoinjector]

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Ixekizumab (Genetical Recombination) Subcutaneous Injection 80mg (Taltz® / トルツ皮下注80mgオートインジェクター)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Ixekizumab (Genetical Recombination) Subcutaneous Injection 80mg (Taltz®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.